EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)

A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons

William B Smith iD, David Nguyen iD, Timothy Clough iD, Jül Schofield iD, Mark R Kagan iD, Jill Kompa iD, YanLing He iD, Eleftheria Maratos-Flier iD, Joanna Jamontt iD, Linh Vong iD, Chad D Schwartzkopf iD, Joseph D Layne und 5 weitere

The Journal of Clinical Endocrinology & Metabolism · 18.02.2025 · 110 (3) · 771-786

DOI: 10.1210/clinem/dgae550 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 16.08.2024. Verfasst von William B Smith und 16 weiteren Autor:innen. Beteiligte Einrichtung: Alliance for Multispecialty Research, LLC, Knoxville, TN 37909, USA. Hauptthemen laut MEDLINE: Obesity, Growth Differentiation Factor 15, Anti-Obesity Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Novartis Biomedical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Growth differentiation factor 15 (GDF15), a divergent member of the TGF-β superfamily, signals via the hindbrain glial-derived neurotrophic factor receptor alpha-like and rearranged during transfection receptor co-receptor (GFRAL-RET) complex. In nonclinical species, GDF15 is a potent anorexigen leading to substantial weight loss. MBL949 is a half-life extended recombinant human GDF15 dimer.

Methods

MBL949 was evaluated in multiple nonclinical species, and then in humans, in 2 randomized and placebo-controlled clinical trials. In the phase 1, first-in-human, single ascending dose trial, MBL949 or placebo was injected subcutaneously to overweight and obese healthy volunteers (n = 65) at doses ranging from 0.03 to 20 mg. In phase 2, MBL949 or placebo was administered subcutaneously every other week for a total of 8 doses to obese participants (n = 126) in 5 different dose regimens predicted to be efficacious based on data from the phase 1 trial.

Results

In nonclinical species, MBL949 was generally safe and effective with reduced food intake and body weight in mice, rats, dogs, and monkeys. Weight loss was primarily from reduced fat, and metabolic endpoints improved. A single ascending dose study in overweight or obese healthy adults demonstrated mean terminal half-life of 18 to 22 days and evidence of weight loss at the higher doses. In the phase 2, weight loss was minimal following biweekly dosing of MBL949 for 14 weeks. MBL949 was safe and generally tolerated in humans over the dose range tested, adverse events of the gastrointestinal system were the most frequent observed.

Conclusion

The prolonged half-life of MBL949 supports biweekly dosing in patients. MBL949 had an acceptable safety profile. The robust weight loss observed in nonclinical species did not translate to weight loss efficacy in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityGrowth Differentiation Factor 15Anti-Obesity AgentsHumansAnimalsMaleFemaleAdultMiddle AgedWeight LossMiceYoung AdultDogsRats

Stichwörter der Autor:innen

GDF15MBL949growth differentiation factor 15obesityrandomized clinical trial

Substanzen

Growth Differentiation Factor 15Anti-Obesity AgentsGDF15 protein, human

Autor:innen und Institutionen

  • Alliance for Multispecialty Research, LLC, Knoxville, TN 37909, USA.
  • Altasciences Clinical Los Angeles, Inc., Cypress, CA 90630, USA.
  • Novartis Biomedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland.
  • Novartis Biomedical Research, Cardiovascular, Renal and Metabolic, Cambridge, MA 02139, USA.
  • Novartis Pharmaceuticals Corporation, Cardiovascular, Renal and Metabolic, East Hanover, NJ 07936, USA.

ORCID-Profile: William B Smith, David Nguyen, Timothy Clough, Jül Schofield, Mark R Kagan, Jill Kompa, YanLing He, Eleftheria Maratos-Flier, Joanna Jamontt, Linh Vong, Chad D Schwartzkopf, Aimee R Usera, Christopher J O'Donnell, Kurt A Heldwein, Ryan S Streeper, Allison B Goldfine

Förderung

  • Novartis Biomedical Research

Zitieren

APA

Smith, W. B., Nguyen, D., Clough, T., Schofield, J., Kagan, M. R., Kompa, J., He, Y., Maratos-Flier, E., Jamontt, J., Vong, L., Schwartzkopf, C. D., Layne, J. D., Usera, A. R., O'Donnell, C. J., Heldwein, K. A., Streeper, R. S., & Goldfine, A. B. (2025). A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons. The Journal of Clinical Endocrinology & Metabolism, 110(3), 771-786. https://doi.org/10.1210/clinem/dgae550

Vancouver

Smith WB, Nguyen D, Clough T, Schofield J, Kagan MR, Kompa J, et al. A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons. The Journal of Clinical Endocrinology & Metabolism. 2025;110(3):771-786. doi:10.1210/clinem/dgae550

BibTeX
@article{Smith2025,
  author = {Smith, William B and Nguyen, David and Clough, Timothy and Schofield, Jül and Kagan, Mark R and Kompa, Jill and He, YanLing and Maratos-Flier, Eleftheria and Jamontt, Joanna and Vong, Linh and Schwartzkopf, Chad D and Layne, Joseph D and Usera, Aimee R and O'Donnell, Christopher J and Heldwein, Kurt A and Streeper, Ryan S and Goldfine, Allison B},
  title = {A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {3},
  pages = {771--786},
  doi = {10.1210/clinem/dgae550}
}
Kostenlos starten →